相似文献
1
A retrospective analysis of a sirolimus/prograf regimen for the prevention of acute rejection in recipients of primary mismatched renal allografts.
Transplant Proc. 2002 Aug;34(5):1653-5. doi: 10.1016/s0041-1345(02)02967-6.
2
Sirolimus is effective for prevention of acute rejection in primary mismatched renal allograft recipients.
Transplant Proc. 2001 Feb-Mar;33(1-2):1031-2. doi: 10.1016/s0041-1345(00)02317-4.
3
Safety and efficacy of TOR inhibitors and other immunosuppressive regimens in African-American renal transplant recipients.
Am J Kidney Dis. 2001 Oct;38(4 Suppl 2):S11-5. doi: 10.1053/ajkd.2001.27505.
4
Observations regarding the use of sirolimus and tacrolimus in high-risk cadaveric renal transplantation.
Clin Transplant. 2004 Feb;18(1):53-61. doi: 10.1111/j.1399-0012.2004.00116.x.
5
Conversion to rapamycin in renal allograft recipients with biopsy-proven calcineurin inhibitor-induced nephrotoxicity.
Transplant Proc. 2001 Nov-Dec;33(7-8):3234-5. doi: 10.1016/s0041-1345(01)02375-2.
6
Steroid withdrawal in renal transplant recipients.
Transplant Proc. 2000 Feb;32(1A Suppl):14S-15S. doi: 10.1016/s0041-1345(00)00811-3.
7
Mizoribine in combination therapy with tacrolimus for living donor renal transplantation: analysis of a nationwide study in Japan.
Transplant Proc. 2005 Mar;37(2):843-5. doi: 10.1016/j.transproceed.2004.12.288.
8
Tacrolimus/sirolimus versus tacrolimus/mycophenolate in kidney transplantation: improved 3-year graft and patient survival in recent era.
Transplantation. 2009 Jun 15;87(11):1712-9. doi: 10.1097/TP.0b013e3181a60431.
9
Randomized trial of three different immunosuppressive regimens to prevent chronic renal allograft rejection.
Transplant Proc. 2002 Aug;34(5):1610-1. doi: 10.1016/s0041-1345(02)03042-7.
10
Improved outcome of minor-mismatched living renal allografts under tacrolimus immunosuppression.
Transplant Proc. 2002 Aug;34(5):1668-70. doi: 10.1016/s0041-1345(02)02973-1.
Zotero 插件